Roche Holdings Ltd ADR (RHHBY)

$40.53 -0.22 (-0.54%)
Market Cap 256.44B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 13.56
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 851,106
Avg Vol 1,365,222
Day's Range N/A - N/A
Shares Out 6.36B
Stochastic %K 94%
Beta 0.46
Analysts Hold
Price Target $43.38

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Tradermane
Tradermane Aug. 21 at 5:12 PM
$CGTX $LLY $RHHBY $BIIB $PRTA
0 · Reply
Guptasulo
Guptasulo Aug. 21 at 4:58 PM
$CGTX $LLY $RHHBY $BIIB $PRTA Sharing again for those who are not familiar as to why CGTX stands far apart from the rest. CGTX received highest funding NIA/NIH. Sponsor ACTC(gold standard) selects partners rigorously based on merit. Others (monoclonal or oral) slow down AD over 12-18 months and that too between 25-49%. CGTX over 26 weeks, slows AD by 95%, is unprecedented. CGTX has Key Opinion Leaders, none other has as many peer reviewed articles. Potential to reverse AD. (None other is even close) What does FDA think about the ph2 trial results? CGTX trial over 6 months trial which no other has ever received. Next Ph3 trial for DLB(with BTD) Partnership followed by two trials for AD and DLB. (probably to run in tandem)
0 · Reply
Quantumup
Quantumup Aug. 21 at 10:43 AM
Jefferies assumed coverage on $SRRK at a Buy rating and a $50 price target. $RHHBY - $PTCT $BIIB - $IONS NVS BHVN Jefferies said in its research note: We expect apitegromab to be approved in SMA (broad label in ≥2y, types 1-4, ambulatory/non-ambulatory) w/ pot'l 1Q PDUFA delay (currently Sept 22) due to procedural observations from recent FDA site inspection. We model $1.8B risk-adj PS (POS 90% in ≥2y & 50% in <2y). Outside SMA, we see optionality w/ api/SRK-439 in other neuromuscular disorders (DMD/FSHD) & obesity (via partnership).
0 · Reply
Quantumup
Quantumup Aug. 20 at 3:56 PM
Piper Sandler (Aug. 18)🏁 $NUVL at an Overweight/$112. $RHHBY $PFE TAK NVS ABBV LLY JNJ $ZLAB $NUVB Piper Sandler said in its initiation report: Investors largely view $NUVL as a high quality precision oncology company but seem to be in a waiting pattern until we get closer to the 1L ALK data in a few years. We think the Street underestimates the near-term value creation over the next 18 months as we get (1) updated Ph II neladalkib data in 2L+ ALK NSCLC later this year which will confirm the degree of differentiation vs. lorlatinib, and by indirect comparison vs. alectinib, (2) initial commercial sales from zidesamtinib in 2026 in the ROS1 market which we think investors undervalue, and 3) potential initial data for NVL-330 in HER2+ NSCLC next year, in our view.
0 · Reply
Quantumup
Quantumup Aug. 20 at 11:17 AM
Raymond James Doubles Down on $VKTX (SB-$122) after Y'day's First Look Note and said that it's becoming convinced that not only is '2735 competitive, but c/b the best oral incretin w/@ least 12wks of pbo-controlled data currently in clinical development. $LLY $NVO $GPCR $RHHBY Raymond James in its note to investors said:
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Aug. 19 at 10:05 PM
$LMDX $RHHBY Veronique Ameye is now the CEO of ElectraDX, as of June 2025. Google it. WHAT THE FUCK. WAS THAT PART OF THE SHADY DEAL?!?!?!?!?!??!?!?!?!
1 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Aug. 19 at 10:01 PM
$RHHBY
0 · Reply
Quantumup
Quantumup Aug. 19 at 6:35 PM
Baird reiterated $SLNO Outperform-$121 and said, 'Buyers on Pullback Following Short Report.' $AARD $RYTM $ACAD $BIIB $RHHBY Baird additionally said in its note: The Soleno short report, published on Friday, claims Vykat is a ticking safety time bomb and that the PWS physician and patient communities are generally averse to trying Vykat, both of which we think are sensationalized. We live in the age of anecdotal evidence, so we don't want to underestimate the risk of some Facebook posts. However, we think the safety profile over hundreds of patients treated commercially remains consistent with the clinical trial experience, and we expect the impressive early growth to continue.
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Aug. 19 at 5:23 PM
$LMDX $RHHBY Lots of inconsistencies with respect to statements from joint liquidators and CMA. You're running out of time to get your story straight, Roche.
0 · Reply
M3l1MCK
M3l1MCK Aug. 19 at 5:16 PM
$LMDX $RHHBY HURRY UP AND PAY US OUT!!!! It's long overdue!!!
0 · Reply
Latest News on RHHBY
No data available.
Tradermane
Tradermane Aug. 21 at 5:12 PM
$CGTX $LLY $RHHBY $BIIB $PRTA
0 · Reply
Guptasulo
Guptasulo Aug. 21 at 4:58 PM
$CGTX $LLY $RHHBY $BIIB $PRTA Sharing again for those who are not familiar as to why CGTX stands far apart from the rest. CGTX received highest funding NIA/NIH. Sponsor ACTC(gold standard) selects partners rigorously based on merit. Others (monoclonal or oral) slow down AD over 12-18 months and that too between 25-49%. CGTX over 26 weeks, slows AD by 95%, is unprecedented. CGTX has Key Opinion Leaders, none other has as many peer reviewed articles. Potential to reverse AD. (None other is even close) What does FDA think about the ph2 trial results? CGTX trial over 6 months trial which no other has ever received. Next Ph3 trial for DLB(with BTD) Partnership followed by two trials for AD and DLB. (probably to run in tandem)
0 · Reply
Quantumup
Quantumup Aug. 21 at 10:43 AM
Jefferies assumed coverage on $SRRK at a Buy rating and a $50 price target. $RHHBY - $PTCT $BIIB - $IONS NVS BHVN Jefferies said in its research note: We expect apitegromab to be approved in SMA (broad label in ≥2y, types 1-4, ambulatory/non-ambulatory) w/ pot'l 1Q PDUFA delay (currently Sept 22) due to procedural observations from recent FDA site inspection. We model $1.8B risk-adj PS (POS 90% in ≥2y & 50% in <2y). Outside SMA, we see optionality w/ api/SRK-439 in other neuromuscular disorders (DMD/FSHD) & obesity (via partnership).
0 · Reply
Quantumup
Quantumup Aug. 20 at 3:56 PM
Piper Sandler (Aug. 18)🏁 $NUVL at an Overweight/$112. $RHHBY $PFE TAK NVS ABBV LLY JNJ $ZLAB $NUVB Piper Sandler said in its initiation report: Investors largely view $NUVL as a high quality precision oncology company but seem to be in a waiting pattern until we get closer to the 1L ALK data in a few years. We think the Street underestimates the near-term value creation over the next 18 months as we get (1) updated Ph II neladalkib data in 2L+ ALK NSCLC later this year which will confirm the degree of differentiation vs. lorlatinib, and by indirect comparison vs. alectinib, (2) initial commercial sales from zidesamtinib in 2026 in the ROS1 market which we think investors undervalue, and 3) potential initial data for NVL-330 in HER2+ NSCLC next year, in our view.
0 · Reply
Quantumup
Quantumup Aug. 20 at 11:17 AM
Raymond James Doubles Down on $VKTX (SB-$122) after Y'day's First Look Note and said that it's becoming convinced that not only is '2735 competitive, but c/b the best oral incretin w/@ least 12wks of pbo-controlled data currently in clinical development. $LLY $NVO $GPCR $RHHBY Raymond James in its note to investors said:
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Aug. 19 at 10:05 PM
$LMDX $RHHBY Veronique Ameye is now the CEO of ElectraDX, as of June 2025. Google it. WHAT THE FUCK. WAS THAT PART OF THE SHADY DEAL?!?!?!?!?!??!?!?!?!
1 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Aug. 19 at 10:01 PM
$RHHBY
0 · Reply
Quantumup
Quantumup Aug. 19 at 6:35 PM
Baird reiterated $SLNO Outperform-$121 and said, 'Buyers on Pullback Following Short Report.' $AARD $RYTM $ACAD $BIIB $RHHBY Baird additionally said in its note: The Soleno short report, published on Friday, claims Vykat is a ticking safety time bomb and that the PWS physician and patient communities are generally averse to trying Vykat, both of which we think are sensationalized. We live in the age of anecdotal evidence, so we don't want to underestimate the risk of some Facebook posts. However, we think the safety profile over hundreds of patients treated commercially remains consistent with the clinical trial experience, and we expect the impressive early growth to continue.
0 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Aug. 19 at 5:23 PM
$LMDX $RHHBY Lots of inconsistencies with respect to statements from joint liquidators and CMA. You're running out of time to get your story straight, Roche.
0 · Reply
M3l1MCK
M3l1MCK Aug. 19 at 5:16 PM
$LMDX $RHHBY HURRY UP AND PAY US OUT!!!! It's long overdue!!!
0 · Reply
Quantumup
Quantumup Aug. 19 at 12:08 PM
Piper Sandler🏁 $DAWN Overweight-$25 and said, Investor sentiment has declined following the first two 2025 earnings reports given concern around the potential plateauing of Ojemda ~1 year into launch. $RHHBY $NVS $PFE $BMY ALPMY Piper Sandler additionally said in its $DAWN initiation: We think the stock move is overdone and that these early decelerations are simply artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies. And while the growth may be more gradual that the Street originally expected, we continue to believe the clinical data will support strong penetration longer term.
1 · Reply
Quantumup
Quantumup Aug. 18 at 6:09 PM
Guggenheim reiterated $SYRE Buy-$65-Top Pick & said 'DUET readout remains a key focus for investors, and we think that $JNJ could disclose the data at UEG 2025 [#UEGWEEK] (although we could be waking up to a press release imminently).' $JNJ $RHHBY $MRK Guggenheim said in its research report: Last week, we hosted a series of investor meetings with $SYRE's CEO (Cameron Turtle), CFO (Scott Burrows), and VP of Finance & IR (Eric Mclntyre). Key takeaways include:
0 · Reply
Quantumup
Quantumup Aug. 18 at 12:28 PM
H.C. Wainwright⬆️ $CELC's PT to $66 from $50, reit'd Buy and and said that recent 'Topline Data From The WT Cohort Are Very Supportive Of FDA Approval' after Celcuity reported 2Q25 financial and operating results. $AZN $PFE $RHHBY $NVS ARVN LLY H.C. Wainwright said in its note: Management confirmed that the company plans to submit a new drug application (NDA) by year-end based on data from the PIK3CA wild-type (WT) cohort of the Phase 3 VIKTORIA-1 study of gedatolisib + fulvestrant At palbociclib for treatment of HR+/HER2- advanced breast cancer in CDK4/6-pretreated patients. We believe the recently disclosed topline data from the WT cohort are very supportive of FDA approval. If successful, the drug could receive marketing approval by mid-2026. H.C. Wainwright additionally said:
0 · Reply
Logic102
Logic102 Aug. 18 at 11:08 AM
$LCTX $RHHBY Roche can either avoid the $620M in milestone payments with a 2025 Buy Out or let a larger competitor buy Lineage and then be forced to pay that competitor the $620M and the generous Royalties plus missing out on the manufacturing Golden Goose and a great pipeline. Buyout incoming within weeks/months, latest would be Q1 26.
1 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Aug. 15 at 10:38 PM
$FCN $LMDX $NDAQ $RHHBY $SPY Everyone is sending out!
0 · Reply
Quantumup
Quantumup Aug. 15 at 4:22 PM
Stifel⬆️the PT on $CELC to $68 from $65 and keeps at a Buy rating. $AZN $PFE $RHHBY $NVS ARVN LLY Stifel said in its note to investors:
0 · Reply
scientificway
scientificway Aug. 15 at 3:28 AM
$RHHBY check out, XTNT, Can not resist to buy
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Aug. 15 at 2:55 AM
$LMDX $RHHBY $SPY $NDAQ $FCN #billgates #gates They robbed us—plain and simple. Every shareholder was misled and stripped of value while insiders enriched themselves. The “conflict of interest” excuse from RZ is nothing more than a smokescreen for self-dealing. They miscalculated badly if they thought we wouldn’t fight back. We are capable of much more than they imagine: • Filing coordinated complaints with the SEC, DOJ, and international regulators • Pursuing legal action for breach of fiduciary duty, securities fraud, and misrepresentation. • Exposing their conduct to the media, investor networks, and industry watchdogs. • Tracking every post-sale move, patent transfer, and insider payout to build an airtight record of wrongdoing. This was not a mistake—it was calculated theft. They believed they were above the law. Pride comes before the fall, and we will make sure that fall is hard and public. We are organized. We are relentless. And we are just getting started.
1 · Reply
johnnygogogo
johnnygogogo Aug. 14 at 7:13 PM
$SRPT Roche is buying this. Mark it. The irony is it will be the success of Arrowhead’s ARO-DM1 that determines the buyout price. cc: $ARWR $RHHBY
3 · Reply
Quantumup
Quantumup Aug. 14 at 2:54 PM
H.C. Wainwright⬆️ $INSM PT to $240 from $120/reit'd Buy. DNA - $RHHBY SGEN - $PFE $LQDA $UTHR MRK AZN H.C. Wainwright said in its note to investors: With the approval of Brinsupri (brensocatib), we believe Insmed in now poised to join the ranks of Genentech and Seagen, to name just two examples, of companies that have successfully deployed the "pipeline-in-a-pill" strategy. We believe that, with time, Brinsupri (and its next generation versions), with its clean safety profile and ease of prescribing, will be shown to have effect in a broad range of neutrophil mediated diseases, beyond the already large commercial opportunity that exists within non-CF bronchiectasis. Coupled with Arikayce's continued commercial success and data which now suggests that TPIP may be a best-in-class inhaled therapy for pulmonary hypertension, we believe Insmed is well positioned to potentially double from current levels. As such we are raising our price target to $240 from $120 and reiterate our Buy rating.
0 · Reply
Fingerlickengood
Fingerlickengood Aug. 14 at 1:44 PM
$CDXS $NVS $RHHBY https://www.globalbankingandfinance.com/USA-TRUMP-TARIFFS-SWISS-PHARMACEUTICALS-c26ffbed-0ffe-459a-8c5b-8a23d80cbc8e
0 · Reply
cheating_stock_investor
cheating_stock_investor Aug. 13 at 5:06 PM
$TEM expecting $SNY and $RHHBY to expand multi year agreements with tempus by year end. This will go over 100 after deals are announced.
1 · Reply